GARP entered its third phase in November 2015. Phase three will see the expansion of the current GARP network consolidated around two hubs, in South and South East Asia and in East and South Africa. Current GARP countries will act as mentors for new members, with collaboration between researchers and policy makers across the network. CDDEP will continue to provide guidance, tools and technical support to ensure that the partnership continues to grow.
The Global Antibiotic Resistance Partnership (GARP) is a project of the Center for Disease Dynamics, Economics & Policy (CDDEP) that has established local policy analysis and policy development capacity related to antibiotic resistance in selected low- and middle-income countries. With support from the Bill & Melinda Gates Foundation, GARP has supported the creation of multi-sectoral national-level working groups whose mandate is to understand and document antibiotic use and antibiotic resistance in the human and animal population in the national context, and to then develop evidence-based proposals to encourage the introduction of measures to preserve antibiotic effectiveness, slow the spread of antibiotic resistance and improve antibiotic access. More than just establishing this capacity in eight diverse countries, CDDEP has developed a modus operandi for establishing a local capacity for antibiotic policy that is not duplicated by any other program, recognizing that country strengths and situations will take them in somewhat different directions.